281 related articles for article (PubMed ID: 22681512)
21. Clinical case reviews and poster sessions in multiple sclerosis spasticity: main outcomes and highlights.
Trojano M; Celius EG; Donzé C; Izquierdo G; Patti F; Pöhlau D
Eur Neurol; 2014; 72 Suppl 1():15-9. PubMed ID: 25278119
[TBL] [Abstract][Full Text] [Related]
22. Multiple sclerosis spasticity daily management: retrospective data from Europe.
Berger T
Expert Rev Neurother; 2013 Feb; 13(3 Suppl 1):3-7. PubMed ID: 23369053
[TBL] [Abstract][Full Text] [Related]
23. Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex
Keating GM
Drugs; 2017 Apr; 77(5):563-574. PubMed ID: 28293911
[TBL] [Abstract][Full Text] [Related]
24. Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.
Syed YY; McKeage K; Scott LJ
Drugs; 2014 Apr; 74(5):563-78. PubMed ID: 24671907
[TBL] [Abstract][Full Text] [Related]
25. Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study).
Messina S; Solaro C; Righini I; Bergamaschi R; Bonavita S; Bossio RB; Brescia Morra V; Costantino G; Cavalla P; Centonze D; Comi G; Cottone S; Danni MC; Francia A; Gajofatto A; Gasperini C; Zaffaroni M; Petrucci L; Signoriello E; Maniscalco GT; Spinicci G; Matta M; Mirabella M; Pedà G; Castelli L; Rovaris M; Sessa E; Spitaleri D; Paolicelli D; Granata A; Zappia M; Patti F;
PLoS One; 2017; 12(8):e0180651. PubMed ID: 28763462
[TBL] [Abstract][Full Text] [Related]
26. Sativex(®) and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis.
Leocani L; Nuara A; Houdayer E; Schiavetti I; Del Carro U; Amadio S; Straffi L; Rossi P; Martinelli V; Vila C; Sormani MP; Comi G
J Neurol; 2015 Nov; 262(11):2520-7. PubMed ID: 26289497
[TBL] [Abstract][Full Text] [Related]
27. Costs and quality of life in multiple sclerosis patients with spasticity.
Svensson J; Borg S; Nilsson P
Acta Neurol Scand; 2014 Jan; 129(1):13-20. PubMed ID: 23683163
[TBL] [Abstract][Full Text] [Related]
28. Who benefits most from THC:CBD spray? Learning from clinical experience.
Koehler J
Eur Neurol; 2014; 71 Suppl 1():10-5. PubMed ID: 24457847
[TBL] [Abstract][Full Text] [Related]
29. THC:CBD spray and MS spasticity symptoms: data from latest studies.
Rekand T
Eur Neurol; 2014; 71 Suppl 1():4-9. PubMed ID: 24457846
[TBL] [Abstract][Full Text] [Related]
30. Sativex in the management of multiple sclerosis-related spasticity: An overview of the last decade of clinical evaluation.
Giacoppo S; Bramanti P; Mazzon E
Mult Scler Relat Disord; 2017 Oct; 17():22-31. PubMed ID: 29055461
[TBL] [Abstract][Full Text] [Related]
31. Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice.
Vermersch P; Trojano M
Eur Neurol; 2016; 76(5-6):216-226. PubMed ID: 27732980
[TBL] [Abstract][Full Text] [Related]
32. Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practice.
Flachenecker P; Henze T; Zettl UK
Eur Neurol; 2014; 72(1-2):95-102. PubMed ID: 24943098
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of adding Sativex® spray to spasticity care in Belgium: using bootstrapping instead of Monte Carlo simulation for probabilistic sensitivity analyses.
Oppe M; Ortín-Sulbarán D; Vila Silván C; Estévez-Carrillo A; Ramos-Goñi JM
Eur J Health Econ; 2021 Jul; 22(5):711-721. PubMed ID: 33880663
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness analysis of interferon beta-1b for the treatment of patients with a first clinical event suggestive of multiple sclerosis.
Caloyeras JP; Zhang B; Wang C; Eriksson M; Fredrikson S; Beckmann K; Knappertz V; Pohl C; Hartung HP; Shah D; Miller JD; Sandbrink R; Lanius V; Gondek K; Russell MW
Clin Ther; 2012 May; 34(5):1132-44. PubMed ID: 22541587
[TBL] [Abstract][Full Text] [Related]
35. Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience.
D'hooghe M; Willekens B; Delvaux V; D'haeseleer M; Guillaume D; Laureys G; Nagels G; Vanderdonckt P; Van Pesch V; Popescu V
BMC Neurol; 2021 Jun; 21(1):227. PubMed ID: 34157999
[TBL] [Abstract][Full Text] [Related]
36. A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols).
Notcutt W; Langford R; Davies P; Ratcliffe S; Potts R
Mult Scler; 2012 Feb; 18(2):219-28. PubMed ID: 21878454
[TBL] [Abstract][Full Text] [Related]
37. Pathophysiology, assessment and management of multiple sclerosis spasticity: an update.
Haas J
Expert Rev Neurother; 2011 Apr; 11(4 Suppl):3-8. PubMed ID: 21449853
[TBL] [Abstract][Full Text] [Related]
38. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis.
Collin C; Ehler E; Waberzinek G; Alsindi Z; Davies P; Powell K; Notcutt W; O'Leary C; Ratcliffe S; Nováková I; Zapletalova O; Piková J; Ambler Z
Neurol Res; 2010 Jun; 32(5):451-9. PubMed ID: 20307378
[TBL] [Abstract][Full Text] [Related]
39. Endocannabinoid pathways and their role in multiple sclerosis-related muscular dysfunction.
Di Marzo V
Expert Rev Neurother; 2011 Apr; 11(4 Suppl):9-14. PubMed ID: 21449854
[TBL] [Abstract][Full Text] [Related]
40. Effect of nabiximols on Goal Attainment Scale scores in patients with treatment-resistant multiple sclerosis spasticity.
Paul F; Silván CV
Neurodegener Dis Manag; 2021 Apr; 11(2):143-153. PubMed ID: 33641348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
